AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Glimpy-MF 1 Tablet

Prescription Icon
Prescription Required

Marketer

Astra Labs

Salt Composition

Glimepiride (1mg) + Metformin (500mg)

Overview Glimpy-MF 1 Tablet

Diabetic patients may find relief with the anti-diabetic medication, GlucoBalance Duo. This dual-action formulation, administered as a single tablet, effectively manages type 2 diabetes in adults by regulating blood glucose. Optimal results require consistent daily intake at the same time, ideally with meals. Dosage is personalized and adjusted by your physician based on your blood sugar response. Continuous use, even with seemingly controlled blood sugar, is crucial. Discontinuing GlucoBalance Duo without medical consultation risks elevated blood sugar and potentially serious complications like kidney disease, vision impairment, neuropathy, and limb loss. Remember, GlucoBalance Duo is one component of a comprehensive diabetes management plan incorporating a balanced diet, regular physical activity, and weight management, as recommended by your doctor. Commonly, GlucoBalance Duo can cause hypoglycemia (low blood sugar). Learn to identify symptoms like tremors, sweating, dizziness, and headaches, and have readily available glucose sources, such as fruit juice or candy, at hand. Alcohol consumption exacerbates this risk and should be limited. Other potential side effects include gastrointestinal upset (nausea, diarrhea, stomach pain), altered taste, headaches, upper respiratory infections, and weight gain. GlucoBalance Duo is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of heart conditions should inform their physician before commencing treatment. Pregnant or nursing women require medical consultation prior to use. Regular blood glucose monitoring is essential, along with periodic blood tests to assess blood cell counts and liver function as directed by your healthcare provider.

Uses of Glimpy-MF 1 Tablet

Managing type 2 diabetes

Major Benefits of Glimpy-MF 1 Tablet:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Glimpy-MF one tablet with a meal.

Common Side effects of Glimpy-MF 1 Tablet:

  • Headache
  • Hypoglycemia (low blood glucose level)
  • Nausea
  • Diarrhea

How to use Glimpy-MF 1 Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. One Glimpy-MF tablet should be taken with a meal.

How Glimpy-MF 1 Tablet works:

Glimpy-MF, a single tablet formulation, combines the antidiabetic agents glimepiride and metformin. Glimepiride, a sulfonylurea, enhances pancreatic insulin secretion, thus reducing blood sugar. Metformin, a biguanide, acts by decreasing hepatic glucose production, slowing intestinal glucose uptake, and improving insulin responsiveness.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Glimpy-MF 1 Tablet and alcohol is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Glimpy-MF 1 Tablet during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against any risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingUNSAFE

Administering Glimpy-MF tablets while breastfeeding poses a significant risk. Evidence indicates potential harm to the infant due to the medication's toxicity.

DrivingDrivingCAUTION

Impaired driving may result from excessively high or low blood glucose levels. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Patients with impaired kidney function should use Glimpy-MF 1 Tablet cautiously, potentially requiring a modified dosage. Severe kidney disease contraindicates the use of Glimpy-MF 1 Tablet. Physician consultation is necessary. Regular monitoring of kidney function is recommended during treatment.

LiverLiverCAUTION

Patients with liver impairment should use Glimpy-MF 1 Tablet cautiously, potentially requiring dose modification. Consult a physician for guidance. A reduced initial dose is typically prescribed for those with mild to moderate liver disease; its use is contraindicated in patients with severe hepatic dysfunction.

What if you forget to take Glimpy-MF 1 Tablet :

Should you forget to take a Glimpy-MF 1 Tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Glimpy-MF 1 Tablet

LabelValue
Potential for Dependence None.
Medication Classification Medication for diabetes

FAQs on Glimpy-MF 1 Tablet

Retain this medication within its original, sealed container. Follow the storage guidelines provided on the packaging. Discard any leftover medication. Ensure the medicine remains inaccessible to children, animals, and other individuals.
Glimpy-MF 1 Tablet use can result in lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. Also termed Metformin-associated lactic acidosis (MALA), this rare but potentially harmful side effect of metformin is particularly risky for individuals with kidney impairment, the elderly, or those who consume significant amounts of alcohol. Symptoms may encompass muscle aches or weakness, lightheadedness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal discomfort, or bradycardia. Should these symptoms arise, discontinue Glimpy-MF 1 Tablet and seek immediate medical attention.
Glimpy-MF, a single-tablet formulation containing glimepiride and metformin, is indicated for managing type 2 diabetes mellitus in adults. This medication enhances glycemic control when used concurrently with a suitable diet and regular physical activity. Glimepiride's mechanism involves stimulating pancreatic insulin secretion, thereby reducing blood glucose. Metformin acts by decreasing hepatic glucose production and augmenting insulin sensitivity. This dual-agent therapy is unsuitable for type 1 diabetes mellitus.
Glimpy-MF 1 Tablet may cause common side effects including low blood sugar (hypoglycemia), taste changes, nausea, abdominal pain, diarrhea, and headache. Rare but serious adverse events such as lactic acidosis may occur. Prolonged use is potentially linked to Vitamin B12 deficiency.
Prolonged Glimpy-MF 1 Tablet use can indeed lead to Vitamin B12 deficiency by disrupting its gastrointestinal absorption. This deficiency, if left unaddressed, may result in anemia, neurological complications such as paresthesia in the extremities, generalized weakness, urinary dysfunction, cognitive impairment, and gait instability. Preventive strategies proposed by some researchers include annual supplemental Vitamin B12 intake.
Indeed, Glimpy-MF 1 Tablet can induce hypoglycemia (low blood glucose). Manifestations of low blood sugar encompass nausea, headache, irritability, hunger pangs, sweating, lightheadedness, tachycardia, and feelings of anxiety or tremor. The likelihood increases with skipped or delayed meals, alcohol consumption, excessive physical activity, or concomitant use of other antidiabetic agents. Consequently, consistent blood glucose monitoring is crucial. Always carry a readily available fast-acting carbohydrate source, such as glucose tablets, honey, or fruit juice.
Consuming alcohol concurrently with Glimpy-MF 1 Tablet is unsafe due to the risk of significantly reduced blood sugar (hypoglycemia) and a heightened probability of lactic acidosis.
Glimpy-MF 1 Tablet
63
MRP 77
18% off